These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Opioid-induced respiratory effects: new data on buprenorphine. Dahan A Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215 [TBL] [Abstract][Full Text] [Related]
6. Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia. Oertel BG; Felden L; Tran PV; Bradshaw MH; Angst MS; Schmidt H; Johnson S; Greer JJ; Geisslinger G; Varney MA; Lötsch J Clin Pharmacol Ther; 2010 Feb; 87(2):204-11. PubMed ID: 19907420 [TBL] [Abstract][Full Text] [Related]
7. American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Jarzyna D; Jungquist CR; Pasero C; Willens JS; Nisbet A; Oakes L; Dempsey SJ; Santangelo D; Polomano RC Pain Manag Nurs; 2011 Sep; 12(3):118-145.e10. PubMed ID: 21893302 [TBL] [Abstract][Full Text] [Related]
8. Assessment of the appropriateness of naloxone administration to patients receiving long-term opioid therapy. Facey C; Brooks D; Boland JW Hosp Pract (1995); 2016; 44(2):86-91. PubMed ID: 26837434 [TBL] [Abstract][Full Text] [Related]
9. The partial 5-hydroxytryptamine1A receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans. Oertel BG; Schneider A; Rohrbacher M; Schmidt H; Tegeder I; Geisslinger G; Lötsch J Clin Pharmacol Ther; 2007 Jan; 81(1):59-68. PubMed ID: 17186000 [TBL] [Abstract][Full Text] [Related]
10. The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression. Lötsch J; Skarke C; Schneider A; Hummel T; Geisslinger G Clin Pharmacol Ther; 2005 Sep; 78(3):278-87. PubMed ID: 16153398 [TBL] [Abstract][Full Text] [Related]
11. Respiratory depression with opioids. Dahan A J Pain Palliat Care Pharmacother; 2007; 21(1):63-6. PubMed ID: 17430835 [TBL] [Abstract][Full Text] [Related]
12. Treating oversedation and respiratory depression. Bumpus S Nursing; 1998 Dec; 28(12):22. PubMed ID: 9987273 [No Abstract] [Full Text] [Related]
13. The development of a respiratory assessment tool. Benham L; Benbow H; Hansen C Nurs Times; 2003 Jun 10-16; 99(23):52-5. PubMed ID: 12838650 [TBL] [Abstract][Full Text] [Related]
14. ASPMN survey--nurses' practice patterns related to monitoring and preventing respiratory depression. Willens JS; Jungquist CR; Cohen A; Polomano R Pain Manag Nurs; 2013 Mar; 14(1):60-5. PubMed ID: 23452528 [TBL] [Abstract][Full Text] [Related]
15. Implementation of solutions to reduce opioid-induced oversedation and respiratory depression. Meisenberg B; Ness J; Rao S; Rhule J; Ley C Am J Health Syst Pharm; 2017 Feb; 74(3):162-169. PubMed ID: 27993764 [TBL] [Abstract][Full Text] [Related]
17. Monitoring for opioid-induced advancing sedation and respiratory depression: ASPMN membership survey of current practice. Jungquist CR; Willens JS; Dunwoody DR; Klingman KJ; Polomano RC Pain Manag Nurs; 2014 Sep; 15(3):682-93. PubMed ID: 24657237 [TBL] [Abstract][Full Text] [Related]
18. Reversal of morphine, methadone and heroin induced effects in mice by naloxone methiodide. Lewanowitsch T; Miller JH; Irvine RJ Life Sci; 2006 Jan; 78(7):682-8. PubMed ID: 16102783 [TBL] [Abstract][Full Text] [Related]
19. [Care of acute respiratory insufficiency due to etorphine intoxication treated by naloxone]. Wang YP; Wang J Zhonghua Hu Li Za Zhi; 1996 Oct; 31(10):591-2. PubMed ID: 9295537 [No Abstract] [Full Text] [Related]